文献速递血栓与止血

下一代FVIIIa模拟双特异性抗体NXT007:在止血与血栓形成临床前模型中的评估

Next-generation FVIIIa-mimetic bispecific antibody NXT007: evaluation in preclinical models of hemostasis and thrombosis.
PubMed 文献 · Blood Adv · 2026-01-01

NXT007是正在1/2期试验中的下一代FVIIIa模拟双特异性抗体,由优化艾美赛珠单抗骨架开发。本文在多种体外和体内临床前模型中直接比较NXT007与艾美赛珠单抗,显示NXT007在促凝血和抗纤溶方面效力更强,且在氯化铁颈动脉损伤模型中无促血栓形成特征。

要点

  • 在HA样血浆中,NXT007比艾美赛珠单抗更高效地增加TF触发的凝血酶生成峰值,较低浓度即达峰且最大效应更高。
  • NXT007抗纤溶效力约为艾美赛珠单抗的20倍,纠正HA样血凝块时间及动力学的效力约为23倍。
  • 在氯化铁颈动脉损伤模型中,NXT007与艾美赛珠单抗在血浆浓度约20至200 μg/mL时对最大血流下降无影响。

核心结论

  • 数据支持NXT007正在进行的临床评估,并提示其可大幅提高血友病A患者的治疗效力。

研究设计与样本

  • 使用多种体外和体内止血与血栓形成临床前模型,直接比较NXT007与艾美赛珠单抗。

主要发现

  • 在HA样血浆中,NXT007与艾美赛珠单抗均增加TF触发的凝血酶生成峰值,NXT007效力更强,较低浓度即达峰且最大效应更高。
  • NXT007与艾美赛珠单抗均剂量依赖性延迟纤溶,NXT007抗纤溶效力约为艾美赛珠单抗的20倍。
  • 在旋转血栓弹力术中,两者均纠正HA样血的凝血时间及动力学,NXT007效力约为艾美赛珠单抗的23倍。
  • 在胶原/TF包被流动腔中,两者均增加纤维蛋白沉积而不增加血小板黏附,NXT007最大效应更大且较低浓度即达。
  • 在HA小鼠尾静脉横断模型中,NXT007控制出血的效力强于艾美赛珠单抗。

关键数值与推荐

  • 在氯化铁颈动脉损伤模型中,NXT007与艾美赛珠单抗在血浆浓度约20至200 μg/mL时对最大血流下降无影响。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

NXT007 is a next-generation factor VIIIa (FVIIIa)-mimetic bispecific antibody currently in phase 1/2 trials. It was developed by optimizing the framework of emicizumab to achieve hemostatic normalization in people with hemophilia A (PwHA). Here, we provide a direct comparison of NXT007 with emicizumab, using a wide range of in vitro and in vivo preclinical models of hemostasis and thrombosis. Both NXT007 and emicizumab increased tissue factor (TF)-triggered peak height thrombin generation when spiked into HA-like (FVIII-neutralized) plasma, with NXT007 being more potent than emicizumab, achieving peak at lower concentrations and producing a higher maximum effect. NXT007 and emicizumab delayed fibrinolysis in a dose-dependent manner, with NXT007 having ∼20-fold more potent antifibrinolytic effect. Both bispecific antibodies corrected clotting times and kinetics of HA-like blood, measured by rotational thromboelastometry, with NXT007 being ∼23-fold more potent. In collagen/TF-coated flow chambers perfused with HA-like blood at arterial shear rates, NXT007 and emicizumab increased fibrin deposition without increasing platelet adherence; the maximum effect of NXT007 was greater than that of emicizumab and was achieved at lower concentration. Following tail vein transection in HA mice, NXT007 was more potent than emicizumab in controlling bleeding. In a ferric chloride carotid injury model, the administration of NXT007 and emicizumab at plasma concentrations of ∼20 to 200 μg/mL had no effect on maximum blood flow reduction, indicating that they do not present a prothrombotic profile in this model. Overall, our data support the ongoing clinical evaluation of NXT007 and suggest that it can substantially improve therapeutic efficacy for PwHA.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Locke M, Albiez J, Receveur N, et al. Next-generation FVIIIa-mimetic bispecific antibody NXT007: evaluation in preclinical models of hemostasis and thrombosis. Blood Adv. 2026. PMID: 41269788. doi:10.1182/bloodadvances.2025018215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。